Stock Market Reviews

NTLA (Intellia Therapeutics, Inc.) News

Get the latest news, insights, and market updates on NTLA (Intellia Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• More Drugs to Fight High Cholesterol Are Emerging
  The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon. Certain patients already can take a twice-yearly injection, sold by Novartis as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.
  Nov 8, 2025 - $NTLA
• Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
  Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
  Nov 7, 2025 - $NTLA
• 2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
  Wall Street may be overestimating these companies' potential.
  Nov 7, 2025 - $NTLA
• Intellia Therapeutics Says a Patient Died in Gene Editing Trial
  Nex-z is the most closely watched drug in Intellia’s development pipeline. The company said in September that it planned to submit the drug for regulatory approval in 2028.
  Nov 7, 2025 - $NTLA
• Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies
  Intellia Therapeutics stock crashed Friday after a patient in its gene-editing study died following serious increases in liver enzymes.
  Nov 7, 2025 - $NTLA
• Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
  Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +9.80% and -12.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $NTLA
• Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
  Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo
  Nov 6, 2025 - $NTLA
• MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
  Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
  Nov 5, 2025 - $NTLA
• VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
  VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
  Nov 5, 2025 - $NTLA
• AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
  Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
  Nov 4, 2025 - $NTLA